---
title: "CONCORD HC GP Guangzhou Hospital Proton Center added over 80 new proton therapy patients in a single month"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271156040.md"
description: "CONCORD HC GP announced that its Guangzhou Hospital Proton Center has officially been in operation for one year. All four proton therapy rooms have been fully utilized, providing proton therapy services to a total of 550 patients, with more than 80 new patients added each month. In July 2025, the Guangzhou Hospital Proton Center completed the country's first proton treatment for ocular choroidal malignant melanoma"
datetime: "2025-12-31T01:07:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271156040.md)
  - [en](https://longbridge.com/en/news/271156040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271156040.md)
---

# CONCORD HC GP Guangzhou Hospital Proton Center added over 80 new proton therapy patients in a single month

CONCORD HC GP (02453.HK) announced that its Guangzhou Hospital Proton Center has officially been in operation for one year. All four proton treatment rooms have been fully utilized, providing proton therapy services to a total of 550 patients, with more than 80 new patients added each month. In July 2025, the Guangzhou Hospital Proton Center completed the country's first proton treatment for malignant melanoma of the choroid in the eye

### Related Stocks

- [02453.HK](https://longbridge.com/en/quote/02453.HK.md)

## Related News & Research

- [Concord Healthcare Completes HK$68 Million Convertible Bond Issue Under General Mandate](https://longbridge.com/en/news/286260367.md)
- [Concord Healthcare to Raise HK$68 Million via Convertible Bonds for Debt Repayment and Working Capital](https://longbridge.com/en/news/285858181.md)
- [Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center](https://longbridge.com/en/news/286662783.md)
- [17:16 ETPROCURE INTRODUCES NEW AWARENESS INITIATIVE TO EDUCATE PATIENTS ABOUT PROTON THERAPY](https://longbridge.com/en/news/286470195.md)
- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)